Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

January 11, 2017 07:30 ET | Source: TG Therapeutics, Inc.

TG Therapeutics Announces Completion of Enrollment and B-cell Depletion Data from Part 1 of Ongoing Phase 2 Multiple Sclerosis Study

Early data demonstrates rapid and profound B-cell reductions in MS patients treated with TG-1101 with median B-cell reduction of 99% TG-1101 was well tolerated with no grade 3/4 adverse events...
January 09, 2017 07:30 ET | Source: TG Therapeutics, Inc.

TG Therapeutics Announces Orphan Drug Designation for the Combination of TG-1101 and TGR-1202 for Treatment of Chronic Lymphocytic Leukemia

NEW YORK, Jan. 09, 2017 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ:TGTX) today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation...
January 09, 2017 07:30 ET | Source: TG Therapeutics, Inc.

TG Therapeutics, Inc. to Present at the 35th Annual J.P. Morgan Healthcare Conference

NEW YORK, Jan. 09, 2017 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (Nasdaq:TGTX) today announced that Michael S. Weiss, the Company’s Executive Chairman and Chief Executive Officer, will present at...
January 04, 2017 07:30 ET | Source: TG Therapeutics, Inc.

TG Therapeutics, Inc. Announces Investigator Initiated Trial at the University of Nebraska Medical Center to Study TGR-1202 in Combination with Ibrutinib in Patients with Relapsed or Refractory Diffuse Large B-cell Lymphoma

NEW YORK, Jan. 04, 2017 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ:TGTX) today announced the opening of an investigator initiated Phase 2 study at the University of Nebraska Medical Center...
December 16, 2016 09:30 ET | Source: TG Therapeutics, Inc.

TG Therapeutics, Inc. Announces Publication of Clinical Data from the Phase 2 Trial of TG-1101 (ublituximab) in Combination with Ibrutinib in the British Journal of Haematology

NEW YORK, Dec. 16, 2016 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ:TGTX) announced the publication of clinical data from a Phase 2 study of TG-1101 (ublituximab), the Company's novel...
December 06, 2016 07:30 ET | Source: TG Therapeutics, Inc.

TG Therapeutics, Inc. Announces Double & Triple Combination Therapy Data Presentations at the 58th American Society of Hematology Annual Meeting

Combination of TG-1101, TGR-1202 and bendamustine resulted in 71% ORR, including 43% complete response rate, in relapsed or refractory DLBCL TGR-1202 continues to demonstrate a favorable and...
December 06, 2016 07:00 ET | Source: TG Therapeutics, Inc.

TG Therapeutics, Inc. Announces that the GENUINE Phase 3 Study has Reached Target Enrollment

NEW YORK, Dec. 06, 2016 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ:TGTX), today announced that the target enrollment of 120 patients in the GENUINE Phase 3 study has been met and enrollment...
December 05, 2016 11:15 ET | Source: TG Therapeutics, Inc.

TG Therapeutics, Inc. Announces Oral Data Presentation for TGR-1202 in Combination with Ibrutinib in Patients with Relapsed or Refractory CLL or MCL at the 58th American Society of Hematology Annual Meeting

Combination of TGR-1202 plus ibrutinib is well-tolerated with no Grade 3/4 transaminitis, pneumonitis, diarrhea, or colitis observed, with patients approaching two years on therapy 88% ORR in CLL...
December 05, 2016 07:30 ET | Source: TG Therapeutics, Inc.

TG Therapeutics, Inc. Announces Preclinical Data Presentations for TGR-1202 at the 58th American Society of Hematology Annual Meeting

SAN DIEGO, Dec. 05, 2016 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ:TGTX), announced the presentation yesterday of two preclinical data sets, one oral presentation and one poster...
December 02, 2016 10:00 ET | Source: TG Therapeutics, Inc.

TG Therapeutics, Inc. Recaps Schedule of Data Presentations at the 58th American Society of Hematology Annual Meeting

SAN DIEGO, Dec. 02, 2016 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ:TGTX), today recapped the schedule of data presentations for their lead compounds, TGR-1202, the Company’s once-daily...